PSG announces the results of the industry’s go-to report on specialty drug spend and trend.
With specialty drug costs remaining a top concern and a pipeline bursting with breakthrough therapies, payers can’t afford to manage specialty spend with yesterday’s strategies. The 2025 Artemetrx State of Specialty Spend and Trend Report delivers the critical data you need to stay ahead of the curve.
Key Findings
- Specialty Drug Trend Declines: Specialty drug trend declined from 14.4% in 2023 to 9.6% in 2024 on a gross cost basis, likely driven by greater adoption of biosimilars.
- Claim Utilization Drives Specialty Drug Trend: Claim utilization continued as the primary driver of specialty drug trend, while cost per claim’s contribution to trend decreased meaningfully from 2023 to 2024.
- Cost Per Claim Trend Varies Across Benefits: From 2023 to 2024, cost per claim increased in the medical benefit but decreased in the pharmacy benefit, highlighting the impact of biosimilars for drugs like Humira.
- Biosimilar Market Share Grows: Overall biosimilar market share continued to grow — especially for Lucentis, Epogen/Procrit, and Remicade biosimilars — and Humira biosimilars began to gain traction.
- Humira Remains Top Specialty Drug by Spend: Humira continued as the top specialty drug by spend followed by Stelara and Skyrizi, and Skyrizi, Dupixent, and Rinvoq each had large increases in utilization.
Want report insights directly from our pharmacy benefit experts? Register for our exclusive webinar on August 13th here!
